tiprankstipranks
Novo Nordisk (NVO)
NYSE:NVO

Novo Nordisk (NVO) Stock Forecast & Price Target

4,791 Followers
See the Price Targets and Ratings of:

NVO Analyst Ratings

Moderate Buy
7Ratings
5 Buy
2 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVO Stock 12 Month Forecast

Average Price Target

$148.00
▲(8.79% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $148.00 with a high forecast of $163.00 and a low forecast of $130.00. The average price target represents a 8.79% change from the last price of $136.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"$76","98":"$98","120":"$120","142":"$142","164":"$164"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$163.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$148.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,98,120,142,164],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.05,126.12307692307692,129.19615384615383,132.26923076923077,135.34230769230768,138.41538461538462,141.48846153846154,144.56153846153848,147.6346153846154,150.7076923076923,153.78076923076924,156.85384615384615,159.92692307692306,{"y":163,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.05,124.96923076923076,126.88846153846154,128.8076923076923,130.72692307692307,132.64615384615385,134.5653846153846,136.48461538461538,138.40384615384616,140.3230769230769,142.2423076923077,144.16153846153847,146.08076923076922,{"y":148,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.05,123.58461538461538,124.11923076923077,124.65384615384615,125.18846153846154,125.72307692307692,126.25769230769231,126.79230769230769,127.32692307692308,127.86153846153846,128.39615384615385,128.93076923076924,129.4653846153846,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.79,"date":1685059200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.9,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.82,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.64,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.17,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.65,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.67,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.89,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.44,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.12,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.59,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.86,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.05,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$163.00Average Price Target$148.00Lowest Price Target$130.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$67.48
Sell
-50.40%
Downside
Reiterated
01/31/24
Novo Nordisk (NVO) gains as 2023 sales rise 31%"4Q focus drugs Wegovy below cons as anticipated, but Ozempic 14% Rybelsus 14% ahead as US rebates again lower than norms," the analyst wrote. "US Wegovy starter dose supply began gradually rising in Jan but will be a focus for the call. Better gross margin offset by higher spend for 5% EBIT 5% EPS beats."
J.P. Morgan Analyst forecast on NVO
Unknown Analyst
Not Ranked
J.P. Morgan
Buy
Reiterated
11/13/23
The Outlook for Weight-Loss Drugs Just Got Turbocharged. Its Good for Eli Lilly, Novo Nordisk.J.P. Morgan analysts are also bullish, rating the shares Overweight. Overall we see the strong benefit of Wegovy treatment across multiple outcomes, in particular on all cause mortality significantly boosting both payer and physician adoption of obesity treatments, in particular Novos Wegovy, they said.
Berenberg Bank
Hold
Reiterated
05/08/24

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy NVO and Sell After:
1 Month
Mark PurcellMorgan Stanley
Success Rate
4/5 ratings generated profit
80%
Average Return
+7.52%
reiterated a buy rating 25 days ago
Copying Mark Purcell's trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +7.52% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Success Rate
6/6 ratings generated profit
100%
Average Return
+8.37%
reiterated a buy rating 13 days ago
Copying Michael Nedelcovych's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +8.37% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Success Rate
6/6 ratings generated profit
100%
Average Return
+26.18%
reiterated a buy rating 13 days ago
Copying Michael Nedelcovych's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.18% per trade.
2 Years
Success Rate
6/6 ratings generated profit
100%
Average Return
+49.28%
reiterated a buy rating 13 days ago
Copying Michael Nedelcovych's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +49.28% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVO Analyst Recommendation Trends

Rating
Jan 24
Feb 24
Mar 24
Apr 24
May 24
Strong Buy
0
0
0
0
0
Buy
8
10
10
11
14
Hold
0
0
1
1
2
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
9
11
12
12
16
In the current month, NVO has received 14 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. NVO average Analyst price target in the past 3 months is $148.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

NVO Financial Forecast

NVO Earnings Forecast

Next quarter’s earnings estimate for NVO is $0.80 with a range of $0.74 to $0.90. The previous quarter’s EPS was $0.81. NVO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.
Next quarter’s earnings estimate for NVO is $0.80 with a range of $0.74 to $0.90. The previous quarter’s EPS was $0.81. NVO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.37% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.

NVO Sales Forecast

Next quarter’s sales forecast for NVO is $9.79B with a range of $9.19B to $10.31B. The previous quarter’s sales results were $9.51B. NVO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.24% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.
Next quarter’s sales forecast for NVO is $9.79B with a range of $9.19B to $10.31B. The previous quarter’s sales results were $9.51B. NVO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.24% of the time in the same period. In the last calendar year NVO has Outperformed its overall industry.

NVO Stock Forecast FAQ

What is NVO’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is $148.00.
    What is NVO’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 8.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NVO a Buy, Sell or Hold?
          Novo Nordisk has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Novo Nordisk’s price target?
            The average price target for Novo Nordisk is $148.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $163.00 ,the lowest forecast is $130.00. The average price target represents 8.79% Increase from the current price of $136.04.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of NVO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis